Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients [PDF]
, 2017 Short communication[Abstract] Background. New direct-acting antivirals agents (DAAs) are very safe and well tolerated. Objectives. The purpose of this study is to analyse the efficacy and safety of DAAs in elderly patients, who have co-morbidities and ...
Castro-Iglesias, Ángeles +12 more
core +2 more sources
Reduced healthcare utilisation following successful HCV treatment in HIV co-infected patients with mild liver disease [PDF]
, 2015 New direct-acting antivirals (DAA) for hepatitis C virus (HCV) infection have achieved high cure rates in many patient groups previously considered difficult-to-treat, including those HIV/HCV co-infected.
Clark, S +6 more
core +2 more sources
, 2015 Worldwide, hepatitis C virus (HCV) is a common infection. Due to new antiviral approaches and the approval of direct-acting antiviral agents (DAA), HCV therapy has become more comfortable. Nevertheless, there are special patient groups, in whom treatment
Heinzow, H. (Hauke) +3 more
core +2 more sources
Linezolid for multidrug-resistant tuberculosis. [PDF]
, 2013 Cox, H, Ford, N, Goemaere, E, Hughes, J
core +2 more sources
Sofosbuvir and daclatasvir therapy in patients with hepatitis C‐related advanced decompensated liver disease (
, 2017 Geoffrey W. McCaughan +14 more
openalex +1 more source
Assessing the impact of a combination of sofosbuvir and daclatasvir treatment for hepatitis C virus infection on heart rate, rhythm and heart rate variability using 24-hour ECG monitoring [PDF]
, 2020 Ahmed El Missiri +3 more
openalex +1 more source
UEG Week 2025 Poster Presentations
United European Gastroenterology Journal, Volume 13, Issue S8, Page S803-S1476, October 2025.
wiley +1 more source
Efficacy of Combination Therapy Sofosbuvir, Daclatasvir and Ribavirin in Patients of Hepatitis C [PDF]
, 2021 Muhammad Abdul Quddus +4 more
openalex +1 more source